Peripheral Neuropathy Treatment Market by Type, Therapy, and Geography - Forecast and Analysis 2023-2027

Published: Nov 2022

Pages: 164

SKU: IRTNTR45413

Snapshot

Peripheral Neuropathy Treatment Market Forecast 2023-2027

The global peripheral neuropathy treatment market size is estimated to grow by USD 372.56 million between 2022 and 2027 at a CAGR of 3.81%. The growth of the market depends on several factors, including the increasing prevalence of peripheral neuropathy, the recent drug approvals, and the rising awareness. The established players in the global market are Eli Lilly and Co., Daiichi Sankyo Co. Ltd., Johnson & Johnson, and Grunenthal GmbH. The market is expected to grow at a moderate rate during the forecast period. Established companies are focusing on expanding their product portfolios by investing in the R&D of novel drugs. Key companies are focusing on collaborations and adopting licensing agreement strategies to expand their reach in the global market. The adoption of inorganic growth strategies and pricing strategies by companies will increase the competition among them.

What will the Size of the Peripheral Neuropathy Treatment Market be During the Forecast Period?

To learn more about this report, Download the FREE Report Sample

Market: Key Drivers, Trends, Challenges, and Customer Landscape

The increasing prevalence of peripheral neuropathy is notably driving the market, although factors such as the side effects of the medications used may impede the market. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Driver

The increasing prevalence of peripheral neuropathy is the key factor driving the global market. Peripheral neuropathy refers to the many conditions that involve damage to the nervous system. More than 100 types have been identified.

The etiology of peripheral neuropathy includes physical injury (trauma), diabetes, vascular and blood-related problems or diseases, systemic (body-wide) autoimmune diseases, hormonal imbalance, kidney and liver disorders, certain cancers and benign tumors, chemotherapy drugs, and certain infections. The rising prevalence of diabetes worldwide will lead to an increase in the number of people with this condition. Thus, the increasing prevalence of diabetes across the world is expected to drive the market during the forecast period.

Key Trend

The strong drug pipeline will fuel the global market. The strong pipeline of drugs for this condition from the key companies in the market is expected to drive the market during the forecast period. These drugs are undergoing different phases of clinical trials and are expected to be approved and launched during the forecast period. These drugs will change the market dynamics with a higher impact.

The drugs use various mechanisms and offer different approaches to treating this condition at multiple targets. These drugs will boost the choices available to people suffering from the condition and change the current market dynamics during the forecast period, thus driving the market.

Key Market Challenge

The side effects of the medications used are a major challenge to the global market. this condition occurs when the nerves carrying messages from and to the brain and spinal cord are damaged. The damage caused to these nerves disrupts communication between the brain and other parts of the body. Therefore, to treat this disorder, various drugs (topical and opioid analgesics and NSAIDs), antidepressants (TCAs, SNRIs, and SSRIs), and anticonvulsant drugs (gabapentin, pregabalin, and topiramate) are used. However, these treatments have several side effects.

For instance, opioid drugs should be administered at a low dosage, and the dosage should be increased gradually. This aligned dosage of such drugs will reduce side effects such as sedation, delirium, drowsiness, and nausea. However, if the dosage of opioids is not maintained in a timely fashion, it can worsen the side effects, resulting in physical dependence and addiction. Thus, the side effects of the medications used for this condition are expected to hinder the market during the forecast period.

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their expansion strategies.

Global Market Customer Landscape

Who are the Major Peripheral Neuropathy Treatment Market companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Apotex - The company offers peripheral neuropathy treatment that includes antidepressants such as amitriptyline, pain medication such as oxycodone, anti-seizure medication, and pain-relieving creams.

We also have detailed analyses of the market’s competitive landscape and offer information on 20 market companies, including :

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

What are the Revenue-generating Type Segments in the Market?

Based on type, the market is segmented into diabetic peripheral neuropathy, chemotherapy induced peripheral neuropathy, and others. The market share growth by the diabetic peripheral neuropathy segment will be significant during the forecast period. The diabetic peripheral neuropathy segment is expected to grow during the forecast period. Nerve damage caused by diabetes results in diabetic peripheral neuropathy. In people with diabetic peripheral neuropathy, axonal damage reduces the nerve action potential, thereby inhibiting neuronal signal transmission.

Get a glance at the market contribution of various segments Request a PDF Sample

The pathogenesis of diabetic peripheral neuropathy is complex and is marked by both metabolic and vascular factors. Hyperglycemia is one of the key metabolic events known to cause axonal and microvascular injury. Peripheral neuropathy is the most common risk factor for foot ulcers in diabetic patients. Other risk factors include elevated triglycerides, excess body weight, smoking, and high blood pressure.

Furthermore, our report provides a brief analysis of the historical and forecast market share and their segments along with the reasons for growth from 2017 to 2027. The growth of this segment is primarily attributed to the increasing adoption, which is driven by an increase in the global demand for the Peripheral Neuropathy Treatment Industry.

Which are the Key Regions for the Market?

For insights on the market share of various regions Request PDF Sample now!

North America is projected to account for 33% of the global market share growth by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The market in North America is expected to grow during the forecast period. Factors such as the rising prevalence of peripheral neuropathy, growing awareness of the condition, the presence of key companies, regulatory approval for new drugs, and a strong pipeline of drugs contribute to the market in the region.

Segment Overview

Our report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by type, therapy, and region.

Type Outlook ( USD Million, 2017 - 2027)
- Diabetic peripheral neuropathy
- Chemotherapy-induced peripheral neuropathy
- Others

Therapy Outlook ( USD Million, 2017 - 2027)
- Pharmacological therapies
- Non-pharmacological therapies

Region Outlook ( USD Million, 2017 - 2027)
- North America
  - The U.S.
  - Canada
- Europe
  - The U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- ROW
  - Argentina
  - Australia
  - Rest of the world

Market Analyst Overview

The Market addresses a range of neurological manifestations, catering to patients with conditions like diabetes, thyroid disorders, autoimmune diseases, and others. Treatment options include pharmacological therapies such as duloxetine and vixotrigine, as well as non-pharmacological approaches like Quell technology and percutaneous electrical neurostimulation (PENS) devices. With a significant prevalence rate among geriatric populations, the market experiences steady growth, supported by product launches and advancements in research. Major players like NeuroMetrix, Inc. and Biogen Inc. drive innovation through FDA-approved therapies and breakthrough designations, addressing chronic pain and chemotherapy-induced peripheral neuropathy. As the aging population grows and research funding increases, the market is poised for further expansion, particularly in regions like North America and Europe.

Peripheral Neuropathy Treatment Market Scope
Report Coverage	Details
Page number	164
Base year	2022
Historical year	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 3.81%
Market growth 2023-2027	USD 372.56 million
Market structure	Fragmented
YoY growth (%)	3.56
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 33%
Key countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading companies, Competitive Strategies, Consumer engagement scope
Key companies profiled	Apotex Inc., Assertio Therapeutics Inc., AstraZeneca Plc, Cadila Pharmaceuticals Ltd., Cipla Ltd., Daiichi Sankyo Co. Ltd., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Grunenthal GmbH, Hikma Pharmaceuticals Plc, Johnson & Johnson, Lupin Ltd., Novartis AG, Pfizer Inc., Shionogi & Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and Viatris Inc.
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our market research report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
Precise estimation of the size of the market size and its contribution to the parent market
Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Therapy
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global peripheral neuropathy treatment market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global peripheral neuropathy treatment market 2017 - 2021 ($ million)

4.2 Type Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ million)

4.3 Treatment Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Treatment Segment 2017 - 2021 ($ million)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Type - Market share 2022-2027 (%)

6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type

6.3 Diabetic peripheral neuropathy - Market size and forecast 2022-2027
- Exhibit 34: Chart on Diabetic peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Diabetic peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Diabetic peripheral neuropathy - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Diabetic peripheral neuropathy - Year-over-year growth 2022-2027 (%)

6.4 Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027
- Exhibit 38: Chart on Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Chemotherapy induced peripheral neuropathy - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2022-2027 (%)

6.5 Others - Market size and forecast 2022-2027
- Exhibit 42: Chart on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 43: Data Table on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 44: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Others - Year-over-year growth 2022-2027 (%)

6.6 Market opportunity by Type
- Exhibit 46: Market opportunity by Type ($ million)

7 Market Segmentation by Therapy

7.1 Market segments
- Exhibit 47: Chart on Therapy - Market share 2022-2027 (%)
- Exhibit 48: Data Table on Therapy - Market share 2022-2027 (%)

7.2 Comparison by Therapy
- Exhibit 49: Chart on Comparison by Therapy
- Exhibit 50: Data Table on Comparison by Therapy

7.3 Pharmacological therapies - Market size and forecast 2022-2027
- Exhibit 51: Chart on Pharmacological therapies - Market size and forecast 2022-2027 ($ million)
- Exhibit 52: Data Table on Pharmacological therapies - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Chart on Pharmacological therapies - Year-over-year growth 2022-2027 (%)
- Exhibit 54: Data Table on Pharmacological therapies - Year-over-year growth 2022-2027 (%)

7.4 Non pharmacological therapies - Market size and forecast 2022-2027
- Exhibit 55: Chart on Non pharmacological therapies - Market size and forecast 2022-2027 ($ million)
- Exhibit 56: Data Table on Non pharmacological therapies - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Chart on Non pharmacological therapies - Year-over-year growth 2022-2027 (%)
- Exhibit 58: Data Table on Non pharmacological therapies - Year-over-year growth 2022-2027 (%)

7.5 Market opportunity by Therapy
- Exhibit 59: Market opportunity by Therapy ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 61: Chart on Market share by geography 2022-2027 (%)
- Exhibit 62: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 63: Chart on Geographic comparison
- Exhibit 64: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027
- Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027
- Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027
- Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 Germany - Market size and forecast 2022-2027
- Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.9 China - Market size and forecast 2022-2027
- Exhibit 89: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 90: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 91: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 92: Data Table on China - Year-over-year growth 2022-2027 (%)

9.10 UK - Market size and forecast 2022-2027
- Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.11 Japan - Market size and forecast 2022-2027
- Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%)
- Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 101: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 102: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 103: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 104: Overview on factors of disruption

11.4 Industry risks
- Exhibit 105: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 106: Vendors covered

12.2 Market positioning of vendors
- Exhibit 107: Matrix on vendor position and classification

12.3 Apotex Inc.
- Exhibit 108: Apotex Inc. - Overview
- Exhibit 109: Apotex Inc. - Product / Service
- Exhibit 110: Apotex Inc. - Key offerings

12.4 Assertio Therapeutics Inc.
- Exhibit 111: Assertio Therapeutics Inc. - Overview
- Exhibit 112: Assertio Therapeutics Inc. - Product / Service
- Exhibit 113: Assertio Therapeutics Inc. - Key offerings

12.5 AstraZeneca Plc
- Exhibit 114: AstraZeneca Plc - Overview
- Exhibit 115: AstraZeneca Plc - Product / Service
- Exhibit 116: AstraZeneca Plc - Key news
- Exhibit 117: AstraZeneca Plc - Key offerings

12.6 Cadila Pharmaceuticals Ltd.
- Exhibit 118: Cadila Pharmaceuticals Ltd. - Overview
- Exhibit 119: Cadila Pharmaceuticals Ltd. - Product / Service
- Exhibit 120: Cadila Pharmaceuticals Ltd. - Key offerings

12.7 Cipla Ltd.
- Exhibit 121: Cipla Ltd. - Overview
- Exhibit 122: Cipla Ltd. - Business segments
- Exhibit 123: Cipla Ltd. - Key news
- Exhibit 124: Cipla Ltd. - Key offerings
- Exhibit 125: Cipla Ltd. - Segment focus

12.8 Daiichi Sankyo Co. Ltd.
- Exhibit 126: Daiichi Sankyo Co. Ltd. - Overview
- Exhibit 127: Daiichi Sankyo Co. Ltd. - Business segments
- Exhibit 128: Daiichi Sankyo Co. Ltd. - Key news
- Exhibit 129: Daiichi Sankyo Co. Ltd. - Key offerings
- Exhibit 130: Daiichi Sankyo Co. Ltd. - Segment focus

12.9 Dr Reddys Laboratories Ltd.
- Exhibit 131: Dr Reddys Laboratories Ltd. - Overview
- Exhibit 132: Dr Reddys Laboratories Ltd. - Business segments
- Exhibit 133: Dr Reddys Laboratories Ltd. - Key offerings
- Exhibit 134: Dr Reddys Laboratories Ltd. - Segment focus

12.10 Eli Lilly and Co.
- Exhibit 135: Eli Lilly and Co. - Overview
- Exhibit 136: Eli Lilly and Co. - Product / Service
- Exhibit 137: Eli Lilly and Co. - Key offerings

12.11 Endo International Plc
- Exhibit 138: Endo International Plc - Overview
- Exhibit 139: Endo International Plc - Business segments
- Exhibit 140: Endo International Plc - Key news
- Exhibit 141: Endo International Plc - Key offerings
- Exhibit 142: Endo International Plc - Segment focus

12.12 Hikma Pharmaceuticals Plc
- Exhibit 143: Hikma Pharmaceuticals Plc - Overview
- Exhibit 144: Hikma Pharmaceuticals Plc - Business segments
- Exhibit 145: Hikma Pharmaceuticals Plc - Key offerings
- Exhibit 146: Hikma Pharmaceuticals Plc - Segment focus

12.13 Johnson and Johnson
- Exhibit 147: Johnson and Johnson - Overview
- Exhibit 148: Johnson and Johnson - Business segments
- Exhibit 149: Johnson and Johnson - Key news
- Exhibit 150: Johnson and Johnson - Key offerings
- Exhibit 151: Johnson and Johnson - Segment focus

12.14 Lupin Ltd.
- Exhibit 152: Lupin Ltd. - Overview
- Exhibit 153: Lupin Ltd. - Product / Service
- Exhibit 154: Lupin Ltd. - Key news
- Exhibit 155: Lupin Ltd. - Key offerings

12.15 Novartis AG
- Exhibit 156: Novartis AG - Overview
- Exhibit 157: Novartis AG - Business segments
- Exhibit 158: Novartis AG - Key offerings
- Exhibit 159: Novartis AG - Segment focus

12.16 Pfizer Inc.
- Exhibit 160: Pfizer Inc. - Overview
- Exhibit 161: Pfizer Inc. - Product / Service
- Exhibit 162: Pfizer Inc. - Key news
- Exhibit 163: Pfizer Inc. - Key offerings

12.17 Viatris Inc.
- Exhibit 164: Viatris Inc. - Overview
- Exhibit 165: Viatris Inc. - Business segments
- Exhibit 166: Viatris Inc. - Key offerings
- Exhibit 167: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 168: Inclusions checklist
- Exhibit 169: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 170: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 171: Research methodology
- Exhibit 172: Validation techniques employed for market sizing
- Exhibit 173: Information sources

13.5 List of abbreviations
- Exhibit 174: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

peripheral neuropathy treatment market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis